Krina K. Patel, MD, MSc

Peer-Reviewed Articles

1. Patel KK. Clinical Factors Associated with Venous Thromboembolism in Multiple Myeloma Patients Treated with Daratumumab. Discover Medicine, 2026. e-Pub 2026.
2. Fortuna, GG, Peres, LC, Nazarenko, E, de Menezes Silva Corraes, A, Hovanky, V, Shune, L, McGuirk, J, De Avilla, G, Khouri, J, Dima, D, Gaballa, MM, Dhakal, B, Forsberg, P, Godara, A, Afrough, A, Anderson, L, Herr, M, Davis, JA, Mann, H, Purvey, S, Clark, WB, Htut, M, Beitinjaneh, AM, Pereira, D, Kocoglu, MH, Ferreri, C, Atrash, S, Voorhees, PM, Rossi, A, Shambavi, R, Hashmi, H, Patel, K, Sidana, S, Lin, Y, Hansen, DK, Sborov, D. Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. Blood Advances 9(23):6009-6018, 2025. e-Pub 2025. PMID: 40875887.
3. Shishido, SN, Mason, J, Kamal, M, Setayesh, SM, Vora, A, Berrios, D, Rueda, LM, Patel, K, Manasanch, EE, Orlowski, R, Kuhn, P. Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 41331085.
4. Pasvolsky, O, Dima, D, Feng, L, Dong, W, Richards, TA, Davis, JA, Afrough, A, Vazquez-Martinez, M, Sannareddy, A, Goel, U, Banerjee, R, Khouri, J, Cervoni, F, Gaballa, MM, Lieberman-Cribbin, A, Rana, MS, Julian, K, Ferreri, C, Shune, L, DeJarnette, S, Bhurtel, E, Susanibar-Adaniya, SP, Portuguese, AJ, Hosoya, H, Mikkilineni, L, Kaur, G, Rossi, A, Herr, M, Schrum, D, Lin, C, Raza, S, Lin, Y, Midha, S, Omar, N, Atarsh, S, McGuirk, J, Sborov, D, Voorhees, PM, Anwer, F, Alsina, M, Freeman, C, Garfall, A, Razzo, B, Sidana, S, Cowan, AJ, Anderson, L, Hansen, DK, Richard, S, Patel, K, Lee, HC, Grajales-Cruz, A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40346049.
5. Dima, D, Vazquez-Martinez, M, Davis, JA, Goel, U, Afrough, A, Sannareddy, A, Pasvolsky, O, Razzo, B, Banerjee, R, Khouri, J, Grajales-Cruz, A, Lieberman-Cribbin, A, Rana, MS, Julian, K, DeJarnette, S, Portuguese, AJ, Gaballa, MM, De Avila, G, Susaniba Adaniya, S, Raza, S, Herr, M, Ouchveridze, E, Richards, TA, Hosoya, H, Mikkilineni, L, Kaur, G, Castaneda Puglianini, OA, Rossi, A, Lin, Y, Atrash, S, Sborov, D, Shain, KH, Voorhees, PM, Richard, S, Garfall, A, Hansen, DK, Sidana, S, Patel, K, Cowan, AJ, Anderson, L, Lee, HC, Anwer, F, Ferreri, C, Shune, L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40562770.
6. Sweiss, K, Wagner, C, Anto, E, Greene, T, Sun, R, Gonzalez, R, Castaneda Puglianini, OA, Freeman, C, Ionescu, F, Patel, K, Ferreri, C, Gaballa, MM, Shune, L, McGuirk, J, Sidana, S, Hovanky, V, Khouri, J, Raza, S, Anwer, F, Dima, D, Hashmi, H, Davis, JA, Afrough, A, Kaur, G, Anderson, L, Forsberg, P, Herr, M, Hansen, DK, Hakan Kocoglu, M, Sborov, D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy 31(12):989-999, 2025. e-Pub 2025. PMID: 40972962.
7. Razzo, BM, Midha, S, Portuguese, AJ, Grajales-Cruz, A, de Menezes Silva Corraes, A, Costello, P, Liu, Y, Sperling, AS, Nadeem, O, Dima, D, Banerjee, R, Cowan, AJ, Afrough, A, Anderson, L, Lieberman-Cribbin, A, Kaur, G, Goyal, A, Atrash, S, Ferreri, C, Voorhees, PM, Pasvolsky, O, Lee, HC, Patel, K, Julian, K, Forsberg, P, Herr, M, Chhabra, S, Parrondo, RD, Lin, Y, Chen, A, Susanibar Adaniya, S, Khouri, J, Raza, S, Anwer, F, Vazquez-Martinez, M, Castaneda Puglianini, OA, Sborov, D, Davis, JA, Rossi, A, Shune, L, Bhurtel, J, Hwang, WT, Hansen, DK, Sidana, S, Garfall, A, Richard, S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood cancer discovery 6(6):561-571, 2025. e-Pub 2025. PMID: 40629516.
8. Dhakal, B, Akhtar, O, Fandrei, D, Jensen, A, Banerjee, R, Pan, D, Richard, S, Friend, R, Rees, MJ, Costello, P, Vazquez-Martinez, M, Pasvolsky, O, Wagner, C, Davis, JA, Castaneda Puglianini, OA, Reshef, R, Afrough, A, Dima, D, Bhutani, M, Nadeem, O, Parrondo, RD, Freeman, C, Mikkilineni, L, Raza, S, Anderson, L, Kapoor, P, Hosoya, H, Chhabra, S, Grajales-Cruz, A, Gaballa, MM, Midha, S, Alsina, M, Sborov, D, Patel, K, Lin, Y, Ferreri, C, Gagelmann, N, Kumar, A, Hansen, DK, Cowan, AJ, Costa, LM, Merz, M, Sidana, S. Sequential targeting in multiple myeloma. Blood 146(17):2063-2072, 2025. e-Pub 2025. PMID: 40749169.
9. Lin P, Acharya S, Reyes-Silva F, Basar R, Uprety N, Moreno Rueda LY, Lin P, Gilbert AL, Banerjee PP, Fang D, Zhang C, Nunez Cortes AK, Garcia LM, Daher M, Muniz-Feliciano L, Deyter GM, Woods V, Rawal S, Li P, Jones CM, Shrestha R, Qazilbash MH, Patel KK, Lee HC, Champlin RE, Marin D, Shpall EJ, Orlowski RZ. CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Blood Cancer Discovery. e-Pub 2025.
10. Banerjee R, Kaur G, Razzo BM, Portuguese AJ, Sidana S, Richards T, Grajales-Cruz A, Richard S, Shune L, Khouri J, Dima D, Lee HC, Patel KK, Pasvolsky O, Vazquez-Martinez M, Hansen DK, Afrough A, Davis JA, Hashmi H, Atrash S, Ferreri CJ, Julian KL, Herr MM, Midha S, Costello P, Forsberg P, Silva Corraes ADM, Lin Y, Cowan AJ, Anderson Jr LD, Garfall AL. Predictors of delayed responses to teclistamab in multiple myeloma after initial non-response. AJH:1-5, 2025. e-Pub 2025.
11. Dhodapkar MV, Alsina M, Chung A, Berdeja J, Patel K, Richard S, Vij R, Leleu X, Bergsagel P, Reshef R, Usmani S, Paul B, Wu F, Basudhar D, Thompson E, Zheng X, Dhanda D, Eliason L, Park S, Tran S, Chaudhry M, Siegel DS. Idecabtagene vicleucel in patients with clinical high-risk, newly diagnosed multiple myeloma: KarMMa-2 cohort 2c. Future Oncology. e-Pub 2025.
12. Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
13. Pasvolsky, O, Marcoux, C, Milton, D, Rafaeli, N, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Mohamedi, A, Deen, AF, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplantation and Cellular Therapy 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
14. Kamal, M, Shishido, SN, Mason, J, Patel, K, Manasanch, EE, Orlowski, R, Kuhn, P. Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states. Neoplasia (United States) 66, 2025. e-Pub 2025. PMID: 40482292.
15. Saha, S, Rehman, L, Rehman, A, Darbaniyan, F, Weber, DM, Becnel, M, Gaballa, MM, Thomas, SK, Lee, HC, Chang, C, Arora, R, Menges, M, Corallo, SA, Davila, ML, Locke, FL, Tanner, MR, Neelapu, SS, Shpall, E, Flowers, CR, Orlowski, R, Jenq, RR, Jain, MD, Peterson, CB, Hansen, DK, Saini, N, Patel, K. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Advances 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
16. Dima, D, Afrough, A, Goel, U, Grajales-Cruz, A, Khouri, J, Julian, K, Pasvolsky, O, Banerjee, R, Razzo, B, Ferreri, C, Vazquez-Martinez, M, Davis, JA, Sannareddy, A, Castaneda, O, Raza, S, Portuguese, AJ, Gaballa, MM, Rana, MS, Lieberman-Cribbin, A, DeJarnette, S, Gonzalez, R, Chen, A, Herr, M, Mikkilineni, L, Hosoya, H, Ouchveridze, E, Kaur, G, Rossi, A, Shune, L, Anwer, F, Lin, Y, Richard, S, Sborov, D, Baz, R, Garfall, A, Lee, HC, Anderson, L, Cowan, AJ, Patel, K, Voorhees, PM, Sidana, S, Hansen, DK, Atrash, S, Susanibar-Adaniya, SP. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. Blood Advances 9(14):3408-3417, 2025. e-Pub 2025. PMID: 40198766.
17. Sidana, S, Ahmed, N, Akhtar, O, Brazauskas, R, Oloyede, T, Bye, M, Hansen, DK, Ferreri, C, Freeman, C, Afrough, A, Anderson, L, Dhakal, B, Dhanda, D, Gowda, L, Hashmi, H, Harrison, MJ, Kitali, A, Landau, H, Mirza, AS, Patwardhan, P, Qazilbash, MH, Usmani, S, Patel, K, Nishihori, T, Ganguly, S, Pasquini, MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood 146(2):167-177, 2025. e-Pub 2025. PMID: 40198886.
18. Dima, D, Logue, J, Waqar, SB, Peres, LC, Colin Leitzinger, C, De Avila, G, Smith, EC, Skelson, L, Matte, KL, Blue, BJ, Hovanky, V, Gaballa, MM, Pasvolsky, O, Oswald, LB, Fortuna, GM, Wagner, C, DeJarnette, S, Dillard, C, Perna, F, Mikkilineni, L, Hosoya, H, Freeman, C, Shain, KH, Baz, R, Grajales-Cruz, A, Castaneda Puglianini, OA, Alsina, M, Locke, FL, Shune, L, Sborov, D, Patel, K, Sidana, S, Hansen, DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica 111(1):184-195, 2025. e-Pub 2025. PMID: 40637727.
19. Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
20. Qin, L, Moreno Rueda, LY, Ray, U, Mahmud, I, Tan, L, Lorenzi, PL, Liu, S, Lin, Y, Mery, D, Zhan, F, Shaughnessy, JD, Yi, Q, Acevedo Calado, MJ, Wang, H, Manasanch, EE, Lee, HC, Patel, K, Kuiatse, I, Symer, DE, Orlowski, R. Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma. Blood 145(22):2614-2629, 2025. e-Pub 2025. PMID: 39912779.
21. Hansen, DK, Peres, LC, Dima, D, Richards, A, Shune, L, Afrough, A, Midha, S, Dhakal, B, Kocoglu, MH, Atrash, S, Ferreri, C, Castaneda, O, Davis, JA, Bhurtel, E, McGuirk, J, Wagner, C, Bansal, R, Costello, P, Smith, K, Lieberman-Cribbin, A, De Avila, G, Purvey, S, Hosoya, H, Mikkilineni, L, Oswald, LB, Kaur, G, Pasvolsky, O, Gaballa, MM, Herr, M, Forsberg, P, Janakiram, M, Htut, M, Asoori Maringanti, S, Kalariya, N, Hashmi, H, Reshef, R, Sborov, D, Nadeem, O, Anwer, F, Khouri, J, Raza, S, Atanackovic, D, Alsina, M, Freeman, C, Locke, FL, Voorhees, PM, Anderson, L, Richard, S, Martin, T, Lin, Y, Patel, K, Sidana, S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 43(13):1597-1609, 2025. e-Pub 2025. PMID: 39965175.
22. Manzar, G, Dudzinski, SO, Yoder, A, Seo, A, Nasr, L, Rafei, H, Becnel, M, Patel, K, Lee, HC, Kaufman, GP, Gaballa, MM, Ye, JC, Saini, N, Thomas, SK, Amini, B, Orlowski, R, Dabaja, BS, Pinnix, CC, Gunther, J, Wu, SY, Fang, PQ. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia 25(4):271-284, 2025. e-Pub 2025. PMID: 39709251.
23. Gaballa, MM, Castaneda Puglianini, OA, Cohen, AD, Vogl, DT, Chung, A, Ferreri, C, Voorhees, PM, Hansen, DK, Patel, K. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances 9(5):1171-1180, 2025. e-Pub 2025. PMID: 39729503.
24. Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
25. George, M, Mustafayev, K, Ahmed, S, Thomas, SK, Jiang, Y, Patel, K, Torres, HA. Direct-Acting Antivirals Induce Lymphoproliferative Disease Response in HCV-Infected Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma. Hematological Oncology 43(2), 2025. e-Pub 2025. PMID: 39921915.
26. Moreno Rueda, LY, Wang, H, Akagi, K, Dang, M, Vora, A, Qin, L, Lee, HC, Patel, K, Lin, P, Mery, D, Zhan, F, Shaughnessy, JD, Yi, Q, Song, Y, Jiang, B, Gillison, M, Thomas, SK, Weber, DM, Diao, L, Wang, J, Kuiatse, I, Manasanch, EE, Symer, DE, Orlowski, R. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Reports Medicine 6(2), 2025. e-Pub 2025. PMID: 39855192.
27. Oren Pasvolsky MD, Denai R Milton MS, Tanner PhD MR, Qaiser Bashir MD, Samer A. Srour, Neeraj Y Saini MD, Paul Lin MD, Siddiqui UR, Hina N Khan MD, Asad A Haider MD, Jeremy L Ramdial MD, Yago Nieto MD, Guilin Tang MD, Lakhani K, Yosra M Aljawai MD, Partow Kebriaei MD, Hans C Lee MD, Krina K Patel MD, Sheeba K Thomas MD, Robert Z Orlowski MD, Muzaffar H Qazilbash MD. Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. Transplantation and Cellular Therapy 31(2):S421, 2025. e-Pub 2025.
28. Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
29. Sidana S, Patel K, Peres L, Bansal R, Kocoglu M, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman C, Locke F, Alsina M, Wong S, Herr MM, Htut M, McGuirk J, Sborov D, Khouri J, Martin T, Janakiram M, Lin Y, Hansen D. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. blood 145(1):85-97, 2025. e-Pub 2025.
30. Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, McKiver MP, Rodríguez-Otero P. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144(23):2389–2401, 2024. e-Pub 2024. PMID: 39197072.
31. Fortuna, GG, Banerjee, R, Savid-Frontera, C, Song, J, Segura, CM, Nguyen, JV, Lekakis, L, Fernandez-Pol, S, Samraj, AN, Naresh, KN, Vazquez-Martinez, M, Baz, R, Spiegel, JY, Mikkilineni, L, Gubatan, J, Sidana, S, de Menezes Silva Corraes, A, Kalariya, N, Patel, K, Shim, KG, Fonseca, R, Ferreri, C, Voorhees, PM, Richard, S, Valdes, CR, Sireesha Asoori, A, Wolf, J, Cowan, AJ, Sborov, D, Locke, FL, Lin, Y, Wang, Y, Hansen, DK. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39414769.
32. Krishnan, A, Patel, K, Mohan, M, Jagannath, S, Niesvizky, R, Silbermann, R, Yu, Z, Long, T, McDonnell, SR, Berg, D, Stockerl-Goldstein, K. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. Blood Neoplasia 1(4), 2024. e-Pub 2024. PMID: 40552138.
33. Zanwar, S, Sidana, S, Shune, L, Puglianini, OC, Pasvolsky, O, Gonzalez, R, Dima, D, Afrough, A, Kaur, G, Davis, JA, Herr, M, Hashmi, H, Forsberg, P, Sborov, D, Anderson, L, McGuirk, J, Wagner, C, Lieberman-Cribbin, A, Rossi, A, Freeman, C, Locke, FL, Richard, S, Khouri, J, Lin, Y, Patel, K, Kumar, SK, Hansen, DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 38845015.
34. Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
35. Krishnan AY, Patel KK, Mohan M, Jagannath S, Niesvizky R, Silbermann RW, Yu Z, Long T, McDonnell SR, Berg D, Stockerl-Goldstein KE. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. Blood Neoplasia, 2024. e-Pub 2024.
36. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood 145(1):85-97, 2024. e-Pub 2024. PMID: 39365257.
37. Banerjee R, Fortuna G, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, Lekakis L, Fernandez-Pol S, Samraj A, Naresh K, Vazquez-Martinez M, Baz R, Spiegel J, Mikkilineni L, Gubatan J, Sidana S, Silva Corraes ADM, Kalariya N, Patel K, Shim K, Fonseca R, Ferreri C, Voorhees P, Richard S, Rodriguez C, Asoori S, Wolf J, Cowan A, Sborov D, Locke F, Lin Y, Wang Y, Hansen D. Immune Effector Cell-Associated Enterocolitis following Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma. Blood Cancer Journal, 2024. e-Pub 2024.
38. Kalariya NM, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ, Doyle WN, Castaneda-Puglianini O, Freeman CL, Hovanky V, Hosoya H, Shune LO, Patel KK. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv 8(17):4679-4688, 2024. e-Pub 2024. PMID: 39042903.
39. Ailawadhi S, Arnulf B, Patel KK, Cavo M, Nooka AK, Manier S, Callander NS, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Abrahamsen IW, Baz RC, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja JG, Giralt SA, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda DS, Felten J, Caia A, Cook M, Popa-Mckiver M, Rodriguez-Otero P. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144(23):2389-2401, 2024. e-Pub 2024. PMID: 39197072.
40. Khouri, J, Dima, D, Li, H, Hansen, DK, Sidana, S, Shune, L, Anwer, F, Sborov, D, Wagner, C, Kocoglu, MH, Atrash, S, Voorhees, PM, Peres, LC, Hovanky, V, Simmons, GL, Williams, L, Raza, S, Afrough, A, Anderson, L, Ferreri, C, Hashmi, H, Davis, JA, McGuirk, J, Goldsmith, SR, Borogovac, A, Lin, Y, Midha, S, Nadeem, O, Locke, FL, Baz, R, Hamilton, B, Alsina, M, Sauter, C, Patel, K, Kaur, G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel. Transplantation and Cellular Therapy 30(8):790.e1-790.e16, 2024. e-Pub 2024. PMID: 38834151.
41. Khawaja, F, Ahmed, S, Iyer, S, Sassine, J, Handley, G, Prakash, R, Vanwierren, T, Jackson, J, Zubovskaia, A, Ramdial, JL, Rondon, G, Patel, K, Spallone, A, Ariza Heredia, E, Mulanovich, VE, Angelidakis, G, Jiang, Y, Chemaly, RF. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases 11(8), 2024. e-Pub 2024. PMID: 39086466.
42. Kalariya NM, Hildebrandt MA, Hansen DK, Sidana S, Khouri J, Ferreri CJ, Doyle WN, Castaneda-Puglianini O, Freeman CL, Hovanky V, Hosoya H, Shune LO, Patel KK. Clinical Outcomes After Idecabtagene Vicleucel in Older Multiple Myeloma Patients: A Multicenter Real-world Experience. Blood Advances, 2024. e-Pub 2024.
43. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
44. Zanwar S, Sidana S, Shune L, Castaneda Puglianini OA, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg PA, Sborov DW, Richard S, Khouri J, Lin Y, Patel KK, Kumar S, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Journal of Hematology & Oncology, 2024. e-Pub 2024.
45. Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Larry, Anderson, Fererri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. TCT, 2024. e-Pub 2024.
46. Hansen DK, Patel KK, Peres LC, Kocoglu MH, Shune L, Simmons G, Ferreri CJ, Atrash S, Parrondo RD, Chhabra S, Costello P, Midha S, Alsina M, Voorhees PM, Htut M, Sborov DW, Khouri J, Janakiram M, Lin Y, Sidana S. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). e-Pub 2024.
47. Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
48. Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JR. Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 119(1):193-199, 2024. e-Pub 2024. PMID: 38070713.
49. Alzahrani, K, Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
50. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica 109(5):1514-1524, 2024. e-Pub 2024. PMID: 37855036.
51. Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain DT, Huff CA, Liu Y, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, PharmD, Huo S, Patel KK. Clinician and Administrator Perspectives on Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma. Transplantation and Cellular Therapy 30(2), 2024. e-Pub 2024.
52. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol 20(18):1-15, 2024. e-Pub 2024. PMID: 38651976.
53. Sidana, S, Peres, LC, Hashmi, H, Hosoya, H, Ferreri, C, Khouri, J, Dima, D, Atrash, S, Voorhees, PM, Simmons, GL, Sborov, D, Kalariya, N, Hovanky, V, Bharadwaj, S, Miklos, D, Wagner, C, Kocoglu, MH, Kaur, G, Davis, JA, Midha, S, Janakiram, M, Freeman, C, Alsina, M, Locke, FL, Gonzalez, R, Lin, Y, McGuirk, J, Afrough, A, Shune, L, Patel, K, Hansen, DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica 109(3):777-786, 2024. e-Pub 2024. PMID: 37731379.
54. Delforge, M, Patel, K, Eliason, L, Dhanda, D, Shi, L, Guo, S, Marshall, TS, Arnulf, B, Cavo, M, Nooka, AK, Manier, S, Callander, N, Giralt, S, Einsele, H, Ailawadhi, S, Popa-McKiver, MA, Cook, M, Rodríguez-Otero, P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens. The Lancet Haematology 11(3):e216-e227, 2024. e-Pub 2024. PMID: 38423700.
55. Kalariya, N, Lee, HC, Qazilbash, MH, Patel, K. Secondary monoclonal gammopathy of unknown significance with isotype switching after CAR T-cell therapy for multiple myeloma: A case report. Current Problems in Cancer: Case Reports 13, 2024. e-Pub 2024.
56. Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, Wang H, Lee HC, Patel KK, Wan J, Choudhary RK, Kuiatse I, Pahl A, Orlowski RZ. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Res Sq, 2024. e-Pub 2024. PMID: 38260385.
57. Peres, LC, Oswald, LB, Dillard, C, De Avila, G, Nishihori, T, Blue, BJ, Freeman, C, Locke, FL, Alsina, M, Puglianini, OC, Shune, L, Sborov, D, Wagner, C, Dima, D, Hashmi, H, Davis, JA, Kocoglu, MH, Badros, AZ, Atrash, S, Simmons, GL, Kalariya, N, Ferreri, C, Anderson, L, Afrough, A, Kaur, G, Lin, Y, Liu, L, Nadeem, O, Voorhees, PM, Khouri, J, McGuirk, J, Sidana, S, Hansen, DK, Patel, K. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Advances 8(1):251-259, 2024. e-Pub 2024. PMID: 37855718.
58. Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. Front Immunol 15:1405452, 2024. e-Pub 2024. PMID: 38915401.
59. Pasvolsky, O, Pasyar, S, Bassett Jr, R, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2023. e-Pub 2023. PMID: 38127583.
60. Ferreri, C, Hildebrandt, MA, Hashmi, H, Shune, L, McGuirk, J, Sborov, D, Wagner, C, Kocoglu, MH, Rapoport, AP, Atrash, S, Voorhees, PM, Khouri, J, Dima, D, Afrough, A, Kaur, G, Anderson, L, Simmons, GL, Davis, JA, Kalariya, N, Peres, LC, Lin, Y, Janakiram, M, Nadeem, O, Alsina, M, Locke, FL, Sidana, S, Hansen, DK, Patel, K, Castaneda Puglianini, OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal 13(1), 2023. e-Pub 2023. PMID: 37558706.
61. Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood cancer journal 14(1), 2023. e-Pub 2023. PMID: 38199987.
62. Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Rezvani, K, Champlin, RE, Shpall, E, Lin, P, Qazilbash, MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37137874.
63. Pasvolsky, O, Ghanem, S, Milton, D, Masood, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplantation and Cellular Therapy 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
64. Pasvolsky, O, Milton, D, Masood, A, Sami, SS, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Saeed, A, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma. American Journal of Hematology 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
65. Pasvolsky, O, Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Tewari, P, Crawford-Suber, L, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. British Journal of Haematology 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
66. Zeng, K, Huang, M, Lyu, M, Khoury, J, Ahmed, S, Patel, K, Dropulić, B, Reese-Koc, J, Caimi, PF, Sadeghi, T, Lima, Md, Flowers, CR, Parmar, S. Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells 12(14), 2023. e-Pub 2023. PMID: 37508543.
67. Dang, M, Wang, R, Lee, HC, Patel, K, Becnel, M, Han, G, Thomas, SK, Hao, D, Chu, Y, Weber, DM, Lin, P, Lutter-Berka, Z, Berrios Nolasco, DA, Huang, M, Bansal, H, Song, X, Zhang, J, Futreal, A, Moreno Rueda, LY, Symer, DE, Green, M, Rojas Hernandez, CM, Kroll, M, Afshar-Khargan, V, Ndacayisaba, LJ, Kuhn, P, Neelapu, SS, Orlowski, R, Wang, L, Manasanch, EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
68. Hansen, DK, Sidana, S, Peres, LC, Colin Leitzinger, C, Shune, L, Shrewsbury, A, Gonzalez, R, Sborov, D, Wagner, C, Dima, D, Hashmi, H, Kocoglu, MH, Atrash, S, Simmons, GL, Kalariya, N, Ferreri, C, Afrough, A, Kansagra, AJ, Voorhees, PM, Baz, R, Khouri, J, Alsina, M, McGuirk, J, Locke, FL, Patel, K. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 41(11):2087-2097, 2023. e-Pub 2023. PMID: 36623248.
69. Afrough, A, Alsfeld, LC, Milton, D, Delgado, R, Popat, UR, Nieto, Y, Kebriaei, P, Oran, B, Saini, N, Srour, S, Hosing, C, Cheema, FH, Ahmed, S, Manasanch, EE, Lee, HC, Kaufman, GP, Patel, K, Weber, DM, Orlowski, R, Pinnix, CC, Dabaja, BS, Thomas, SK, Champlin, RE, Shpall, E, Qazilbash, MH, Bashir, Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
70. Kourelis, TV, Bansal, R, Berdeja, JG, Siegel, D, Patel, K, Mailankody, S, Htut, M, Shah, ND, Wong, SW, Sidana, S, Cowan, AJ, Alsina, M, Cohen, AD, Holstein, SA, Bergsagel, PL, Ailawadhi, S, Raje, N, Dhakal, B, Rossi, A, Lin, Y. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation. Transplantation and Cellular Therapy 29(4):255-258, 2023. e-Pub 2023. PMID: 36681151.
71. Shank, BR, Primeaux, B, Yeung, EK, Horowitz, S, Lee, IY, Roccograndi, L, Feng, L, Kaufman, GP, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Weber, DM, Becnel, M, Thomas, SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 23(4):279-290, 2023. e-Pub 2023. PMID: 36797154.
72. Hess, B, Giri, A, Park, Y, Patel, K, Link, BK, Nowakowski, GS, Maliske, SM, Fortin, S, Chavez, JC, Saeed, H, Hill, BT, Mejia Garcia, AV, Maddocks, K, Hanel, W, Wagner-Johnston, ND, Messmer, M, Kahl, BS, Watkins, MP, Alderuccio, JP, Lossos, IS, Nathan, S, Orellana-Noia, VM, Portell, CA, Landsburg, DJ, Ayers, EC, Castillo, JJ. Outcomes of patients with limited-stage plasmablastic lymphoma. American Journal of Hematology 98(2):300-308, 2023. e-Pub 2023. PMID: 36588409.
73. Damron, EP, Qazilbash, MH, Fang, PQ, Wu, SY, Dabaja, BS, Rondon, G, Hosing, C, Champlin, RE, Bashir, Q, Shpall, E, Knafl, M, Lee, HC, Manasanch, EE, Patel, K, Thomas, SK, Orlowski, R, Weber, DM, Pinnix, CC, Gunther, J. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
74. Rodríguez-Otero, P, Ailawadhi, S, Arnulf, B, Patel, K, Cavo, M, Nooka, AK, Manier, S, Callander, N, Costa, LM, Vij, R, Bahlis, NJ, Moreau, P, Solomon, S, Delforge, M, Berdeja, JG, Truppel-Hartmann, A, Yang, Z, Favre-Kontula, L, Wu, F, Piasecki, J, Cook, M, Giralt, S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine 388(11):1002-1014, 2023. e-Pub 2023. PMID: 36762851.
75. Pasvolsky, O, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Tang, G, Saini, N, Ramdial, JL, Masood, A, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
76. Patel, K, Lonial, S. When an embarrassment of riches isn’t enough. Nature Reviews Clinical Oncology 19(10):617-618, 2022. e-Pub 2022. PMID: 35941288.
77. Kalariya, N, Ferreri, C, Dillard, C, Hawkins, MC, Manasanch, EE, Lee, HC, Weber, DM, Thomas, SK, Steiner, RE, Hosing, C, Qazilbash, MH, Popat, UR, Orlowski, R, Hildebrandt, MA, Patel, K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel. Clinical Lymphoma, Myeloma and Leukemia SOHO 2022 22:S446, 2022. e-Pub 2022. PMID: 36164224.
78. Gaballa, MM, Ma, J, Rauf, M, Bassett Jr, R, Pasvolsky, O, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Murphy, R, Rezvani, K, Tang, G, Lin, P, Lee, HC, Patel, K, Ullah, MR, Kaufman, GP, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Shpall, E, Champlin, RE, Orlowski, R, Qazilbash, MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
79. Obaisi, O, Fontillas, RC, Patel, K, Ngo-Huang, AT. Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy. Current oncology reports 24(6):741-749, 2022. e-Pub 2022. PMID: 35267151.
80. Afrough, A, Pasvolsky, O, Ma, J, Srour, S, Bashir, Q, Saini, N, Hosing, C, Popat, UR, Kebriaei, P, Delgado, R, Ullah, MR, Murphy, R, Manasanch, EE, Lee, HC, Kaufman, GP, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
81. Patel, K, Shah, JJ, Feng, L, Lee, HC, Manasanch, EE, Olsem, J, Morphey, A, Huo, XJ, Thomas, SK, Bashir, Q, Qazilbash, MH, Weber, DM, Orlowski, R. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clinical Cancer Research 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
82. Ahmed, S, Zhao, Q, Hanel, W, Qazilbash, MH, Patel, K, Narra, R, Kansagra, AJ, Iqbal, M, Awan, FT, Christian, B, Jaglowski, SM, Kharfan-Dabaja, MA, Hamadani, M, Epperla, N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology 40(1):48-56, 2022. e-Pub 2022. PMID: 34763367.
83. Gaballa, MM, Ma, J, Tanner, MR, Al-Juhaishi, T, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Murphy, R, Rezvani, K, Tang, G, Lee, HC, Patel, K, Kaufman, GP, Manasanch, EE, Ullah, MR, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia and Lymphoma 63(3):710-721, 2022. e-Pub 2022. PMID: 34686083.
84. Shah, ND, Perales, MA, Turtle, CJ, Cairo, MS, Cowan, AJ, Saeed, H, Budde, LE, Tan, A, Lee, Z, Kai, K, Marcondes, MQ, Zalevsky, J, Tagliaferri, M, Patel, K. Phase i study protocol. Future Oncology 17(27):3549-3560, 2021. e-Pub 2021. PMID: 34154392.
85. Srour, S, Saliba, RM, Bashir, Q, Popat, UR, Ahmed, S, Mehta, RS, Delgado, R, Rondon, G, Parmar, S, Kebriaei, P, Hosing, C, Manasanch, EE, Lee, HC, Patel, K, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Nieto, Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
86. Elhammali, A, Amini, B, Ludmir, EB, Gunther, J, Milgrom, SA, Pinnix, CC, Andraos, TY, Yoder, AK, Weber, DM, Orlowski, R, Manasanch, EE, Patel, K, Strati, P, Nair, R, Lee, HC, Thomas, SK, Iyer, SP, Kaufmann, G, Garg, N, Dabaja, BS. New paradigm for radiation in multiple myeloma. Haematologica 105(7):E355-E357, 2020. e-Pub 2020. PMID: 31919088.
87. Cordas dos Santos, DM, Saliba, RM, Patel, R, Bashir, Q, Saini, N, Hosing, C, Kebriaei, P, Khouri, IF, Nieto, Y, Popat, UR, Ahmed, H, Lee, HC, Manasanch, EE, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Champlin, RE, Qazilbash, MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
88. Kunacheewa, C, Lee, HC, Patel, K, Thomas, SK, Amini, B, Srour, S, Bashir, Q, Nieto, Y, Qazilbash, MH, Weber, DM, Feng, L, Orlowski, R, Lin, P, Manasanch, EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
89. Varma, A, Sui, D, Milton, D, Tang, G, Saini, N, Hasan, O, Mukherjee, A, Joseph, JJ, Bashir, Q, Rondon, G, Srour, S, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Mehta, RS, Khouri, IF, Ahmed, H, Iyer, SP, Weber, DM, Thomas, SK, Manasanch, EE, Lee, HC, Patel, K, Ciurea, SO, Shpall, E, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
90. Zong, S, Mi, T, Flores, L, Alpert, A, Olivares, S, Patel, K, Maiti, SN, McNamara, G, Cooper, L, Torikai, H. Very rapid cloning, expression and identifying specificity of T-cell receptors for T-cell engineering. PloS one 15(2), 2020. e-Pub 2020. PMID: 32040512.
91. Bashir, Q, Chamoun, K, Milton, D, Khan, M, Ahmed, S, Mehta, RS, Popat, UR, Kebriaei, P, Nieto, Y, Oran, B, Ciurea, SO, Hosing, C, Khouri, IF, Patel, K, Manasanch, EE, Lee, HC, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leukemia and Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
92. Saini, N, Ma, J, Milton, D, Patel, R, Varma, A, Bashir, Q, Delgado, R, Mukherjee, A, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Tang, G, Mehta, RS, Srour, S, Khouri, IF, Iyer, SP, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH. Impact of autologous transplantation in patients with multiple myeloma with t(11;14). Clinical Cancer Research 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
93. Tabchi, S, Nair, R, Kunacheewa, C, Patel, K, Lee, HC, Thomas, SK, Amini, B, Ahmed, S, Mehta, RS, Bashir, Q, Qazilbash, MH, Weber, DM, Orlowski, R, Alexanian, R, Feng, L, Manasanch, EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
94. Elhammali, A, Milgrom, SA, Amini, B, Gunther, J, Yoder, AK, Ludmir, EB, Moon, BS, Weber, DM, Thomas, SK, Garg, N, Manasanch, EE, Patel, K, Orlowski, R, Lee, HC, Bird, JE, Satcher, R, Lin, PP, Pinnix, CC, Dabaja, BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones. Clinical Lymphoma, Myeloma and Leukemia 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
95. Gowda, L, Shah, MV, Badar, I, Bashir, Q, Shah, ND, Patel, K, Kanagal Shamanna, R, Mehta, RS, Weber, DM, Lee, HC, Manasanch, EE, Shah, AR, Thomas, SK, Parmar, S, Nieto, Y, Orlowski, R, Champlin, RE, Qazilbash, MH. Primary plasma cell leukemia. Bone marrow transplantation 54(7):1089-1093, 2019. e-Pub 2019. PMID: 30446740.
96. Bashir, Q, Thall, PF, Milton, D, Fox, PS, Kawedia, J, Kebriaei, P, Shah, ND, Patel, K, Andersson, BS, Nieto, Y, Valdez, B, Parmar, S, Rondon, G, Delgado, R, Hosing, C, Popat, UR, Oran, B, Ciurea, SO, Lin, P, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Orlowski, R, Williams, LA, Champlin, RE, Qazilbash, MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma. The Lancet Haematology 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
97. Maymani, H, Lin, P, Saliba, RM, Popat, UR, Bashir, Q, Shah, ND, Patel, K, Parmar, S, Kebriaei, P, Hosing, C, Ciurea, SO, Andersson, BS, Shpall, E, Champlin, RE, Srour, S, Qazilbash, MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
98. Chaudhry, M, Steiner, RE, Claussen, C, Patel, K, Lee, HC, Weber, DM, Thomas, SK, Feng, C, Amini, B, Orlowski, R, Feng, L, Manasanch, EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström’s macroglobulinemia. Leukemia and Lymphoma 60(4):964-970, 2019. e-Pub 2019. PMID: 30227761.
99. Hu, B, Thall, PF, Milton, D, Sasaki, K, Bashir, Q, Shah, ND, Patel, K, Popat, UR, Hosing, C, Nieto, Y, Lin, P, Delgado, R, Jorgensen, JL, Manasanch, EE, Weber, DM, Thomas, SK, Orlowski, R, Champlin, RE, Qazilbash, MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leukemia and Lymphoma 60(2):442-452, 2019. e-Pub 2019. PMID: 30032678.
100. Ragon, BK, Mehta, RS, Gulbis, A, Saliba, RM, Chen, J, Rondon, G, Popat, UR, Nieto, Y, Oran, B, Olson, AL, Patel, K, Hosing, C, Qazilbash, MH, Shah, ND, Kebriaei, P, Shpall, E, Champlin, RE, Alousi, AM. Pentostatin therapy for steroid-refractory acute graft versus host disease. Bone marrow transplantation 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
101. Veltri, LW, Milton, D, Delgado, R, Shah, ND, Patel, K, Nieto, Y, Kebriaei, P, Popat, UR, Parmar, S, Oran, B, Ciurea, SO, Hosing, C, Lee, HC, Manasanch, EE, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Bashir, Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
102. Khouri, M, Jabbour, EJ, Gulbis, A, Turturro, F, Ledesma, C, Korbling, M, Samuels, BI, Ahmed, S, Alousi, AM, Ciurea, SO, Marin, D, Patel, K, Popat, UR, Bueso-Ramos, CE, Bassett Jr, R, Khouri, IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
103. Nieto, Y, Valdez, B, Pingali, SR, Bassett Jr, R, Delgado, R, Nguyen, J, Shah, ND, Popat, UR, Jones, R, Andersson, BS, Gulbis, A, Ahmed, S, Bashir, Q, Parmar, S, Patel, K, Myers, AL, Rondon, G, Orlowski, R, Champlin, RE, Qazilbash, MH. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma. The Lancet Haematology 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
104. Shah, ND, Li, L, McCarty, J, Kaur, I, Yvon, E, Shaim, H, Muftuoglu, M, Liu, E, Orlowski, R, Cooper, L, Lee, DA, Parmar, S, Cao, K, Sobieiski, C, Saliba, RM, Hosing, C, Ahmed, S, Nieto, Y, Bashir, Q, Patel, K, Bollard, CM, Qazilbash, MH, Champlin, RE, Rezvani, K, Shpall, E. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
105. Kebriaei, P, Bassett Jr, R, Lyons, GR, Valdez, B, Ledesma, C, Rondon, G, Oran, B, Ciurea, SO, Alousi, AM, Popat, UR, Patel, K, Ahmed, S, Olson, AL, Bashir, Q, Shah, ND, Jones, R, Marin, D, Rezvani, K, Nieto, Y, Khouri, IF, Qazilbash, MH, Hosing, C, Shpall, E, Champlin, RE, Andersson, BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
106. Bock, F, Lu, G, Srour, S, Gaballa, S, Lin, Y, Baladandayuthapani, V, Honhar, M, Stich, M, Shah, ND, Bashir, Q, Patel, K, Popat, UR, Hosing, C, Korbling, M, Delgado, R, Rondon, G, Shah, JJ, Thomas, SK, Manasanch, EE, Isermann, B, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
107. Gaballa, S, Saliba, RM, Srour, S, Lu, G, Brammer, JE, Shah, ND, Bashir, Q, Patel, K, Bock, F, Parmar, S, Hosing, C, Popat, UR, Delgado, R, Rondon, G, Shah, J, Manasanch, EE, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. American journal of hematology 91(10):E442-E447, 2016. e-Pub 2016. PMID: 27420405.
108. Badar, T, Cornelison, AM, Shah, ND, Bashir, Q, Parmar, S, Patel, K, Hosing, C, Popat, UR, Weber, DM, Thomas, SK, Shah, J, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. European Journal of Haematology 97(4):342-347, 2016. e-Pub 2016. PMID: 26773409.
109. Pinnix, CC, Shah, J, Chuang, HH, Costelloe, C, Medeiros, LJ, Wogan, CF, Reed, VK, Smith, GL, Milgrom, SA, Patel, K, Huo, J, Turturro, F, Romaguera, JE, Fayad, LE, Oki, Y, Fanale, MA, Westin, JR, Nastoupil, L, Hagemeister, FB, Rodriguez, MA, Qazilbash, MH, Shah, ND, Bashir, Q, Ahmed, S, Nieto, Y, Hosing, C, Rohren, E, Dabaja, BS. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 16(3):122-128, 2016. e-Pub 2016. PMID: 26795083.
110. Menon, C, Bauer, TW, Kelley, ST, Raz, DJ, Bleier, JI, Patel, K, Steele, K, Prabakaran, I, Shifrin, A, Buerk, DG, Sehgal, CM, Fraker, DL. Tumoricidal activity of high-dose tumor necrosis factor-α is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. International journal of cancer 123(2):464-475, 2008. e-Pub 2008. PMID: 18449880.

Review Articles

1. Raje NS, Cohen AD, Patel KK, van de Donk NWCJ, Richter J, San-Miguel J. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting. Clin Lymphoma Myeloma Leuk 24(6):350-357, 2024. e-Pub 2024. PMID: 38627181.
2. Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clin Lymphoma Myeloma Leuk 24(5):e217-e225, 2024. e-Pub 2024. PMID: 38369437.
3. Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan H, Lee H, Ye C, Patel K, Thomas S, Orlowski RZ, Shpall E, Champlin AR. Multiple Myeloma Patients with a Long Remission After Autologous Hematopoietic Stem Cell Transplantation. Blood Cancer Journal, 2024. e-Pub 2024.
4. Raje, N, Anderson, KC, Einsele, H, Efebera, Y, Gay, F, Hammond, SP, Lesokhin, AM, Lonial, S, Ludwig, H, Moreau, P, Patel, K, Ramasamy, K, Mateos, MV. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37528088.

Other Articles

1. Kamal, M, Shishido, SN, Mason, J, Patel, K, Manasanch, EE, Orlowski, R, Kuhn, P Corrigendum to “Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states” [Neoplasia 66 (2025) 1101189] (Neoplasia (2025) 66, (S1476558625000685), (10.1016/j.neo.2025.101189)). Neoplasia (United States) 69, 2025. PMID: 40915282.
2. Saini, N, Bashir, Q, Milton, D, Tang, G, Delgado, R, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Mehta, RS, Srour, S, Khouri, IF, Weber, DM, Thomas, SK, Lee, HC, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Advances 4(19):4834-4837, 2020. PMID: 33027527.

Editorials

1. Patel, K, Facon, T. Rewriting Risk. Journal of Clinical Oncology 43(24):2661-2663, 2025. PMID: 40680242.

Abstracts

1. Pasvolsky O, Milton DR, Masood A, Shehzad SS, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. Blood Journal, ASH 2022 140(1), 2022. e-Pub 2022.
2. Dhodapkar M, MBBS, Alsina M, MD, Berdeja J, MD, Patel K, MD, MSc, Vij R, MD, MBBS, Leleu X, MD, PhD, Truppel-Hartmann A, MD, Basudhar D, PhD, Thompson E, PhD, Zheng X, PhD, Ananthakrishnan R, PhD, Favre-Kontula L, PhD, Greggio C, PhD, Sternas L, MD, PhD, Siegel DS, MD, PhD. KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation. Blood Journal, ASH 2022, 2022. e-Pub 2022.
3. Patel K, MD, MSc, Shah N, MD, Tan A, MD, Cowan AJ, MD, Turtle CJ, MBBS, PhD, Hofmeister CC, MD, Choi T, MD, Saeed H, MD, Chavez JC, MD, Pianko MJ, MD, Gandhi M, MD, Chaudhry SA, MD, Lee Z, PharmD, Dixit N, PhD, Fanton C, PhD, Wang X, PhD, MBA, Xu H, PhD, Marcondes MQ, MD, PhD, Tagliaferri MA, MD, Zalevsky J, PhD, Perales M, MD. Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood Journal, ASH 2022, 2022. e-Pub 2022.
4. Lee HC, MD, Kaufman GP, MD, Feng L, MS, Murga A, Johnson RJ, PhD, Weber DM, MD, Thomas SK, MD, Bashir Q, MD, Qazilbash MH, MD, Iyer SP, MD, Patel K, MD, MSc, Becnel MR, MD, Manasanch EE, MD, Orlowski RZ, MD, PhD. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. Blood Journal, ASH 2022, 2022. e-Pub 2022.
5. Subramanian NG, MD, Aung FM, MD, Patel K, MD, MSc, Lee HC, MD, Jin S, Young E, MS, Rojas Hernandez CM, MD. Clinical Factors Associated to VTE in Multiple Myeloma Patients Treated with Daratumumab. Blood Journal, ASH 2022, 2022. e-Pub 2022.
6. Khouri J, MD, Li H, MS, Hansen DK, MD, Sidana S, MD, Shune LO, MD, DeJarnette S, Anwer F, MD, Sborov DW, Wagner CB, PharmD, Kocoglu M, MD, Atrash S, MD, Voorhees PM, MD, Valent J, MD, Peres LC, PhD, MPH, Hovanky V, Simmons G, DO, Dima D, MD, Kalariya N, Afrough A, MD, Kaur G, MD, Sannareddy A, MBBS, Ferreri CJ, MD, Davis J, PharmD, McGuirk JP, DO, Locke FL, MD, Baz RC, MD, Hamilton BK, MD, Alsina M, MD, Sauter CS, MD, Hashmi H, MD, Patel K, MD, MSc. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience. Blood Journal, ASH 2022, 2022. e-Pub 2022.
7. Usmani S, Patel K, Hari P, Berdeja J, Alsina M, Vij R, Raje N, Leleu X, Dhodapkar M, Reshef R, Truppel-Hartmann A, Basudhar D, Thompson E, Zheng X, Ananthakrishnan R, Greggio C, Favre-Kontula L, Sternas L, San-Miguel J. KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood Journal, ASH 2022 140(1), 2022. e-Pub 2022.
8. Qazilbash M, Gaballa M, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner M, Bashir Q, Srour S, saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee H, Patel K, Ullah M, Kaufman G, Manasanch E, Kebriaei P, Thomas S, Weber D, Shpall E, Champlin R, Z Orlowski AR. KRD vs. VRD as Induction Before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Bone Marrow Transplantation:BMT-2022-183RR, 2022. e-Pub 2022.
9. Saini N, MD, Ma J, MS, Bashir Q, MD, Delgado R, Rondon G, Popat UR, MD, Hosing C, MD, Nieto Y, MD, Kebriaei P, MD, Alousi AM, MD, Mehta RS, MD, MPH, MS, Srour SA, MD, MS, Khouri IF, MD, Weber DM, MD, Thomas SK, MD, Lee HC, MD, Patel KK, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood Journal, 2020. e-Pub 2020.
10. Becnel MR, MD, Horowitz SB, PharmD, Thomas SK, MD, Iyer SP, MD, Patel KK, MD, Manasanch EE, MD, Weber DM, MD, Kaufman GP, MD, Lee HC, MD, Orlowski RZ, MD, PhD. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood Journal, 2020. e-Pub 2020.
11. Thomas SK, MD, Cha S, PhD, Parshottam SR, MSc, Rao SS, PhD, Olsem JB, BSN, Crumpton BN, Szymura S, PhD, Wang Z, PhD, Anderson A, Feng L, MS, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Neelapu SS, MD, Kwak LW, MD, PhD. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). Blood Journal, 2020. e-Pub 2020.
12. Thomas SK, MD, Shah JJ, MD, Morin A, MA, Morphey AN, MSN, Lee HC, MD, Manasanch EE, MD, Patel KK, MD, Kaufman GP, MD, Iyer SP, MD, Feng L, MS, Amini B, MD, PhD, Qazilbash MH, MD, Bashir Q, MD, Saini N, MD, Srour SA, MD, MS, Johnson RJ, PhD, Crumpton BN, Stafford MD, Weber DM, MD, Orlowski RZ, MD, PhD. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood Journal, 2020. e-Pub 2020.
13. Afrough A, MD, Srour SA, MD, MS, Bashir Q, MD, Saini N, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Delgado R, Murphy R, PA-C, Manasanch EE, MD, Lee HC, MD, Kaufman GP, MD, Patel KK, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation, 2020. e-Pub 2020.
14. Ramdial JL, MD, Ma J, MS*, Milton DR, MS*, Delgado* R, Bashir Q, MD, Srour SA, MD, MS, Saini N, MD, Nieto Y, MD, Hosing C, MD, Popat UR, MD, Murphy R, PA-C*, Lee HC, MD, Patel KK, MD, Manasanch EE, MD, Thomas SK, MD, Kaufman GP, MD*, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood Journal, 2020. e-Pub 2020.
15. Srour SA, MD, MS, Bashir Q, MD, Milton DR, MS, Nieto Y, MD, Mehta RS, MD, MPH, MS, Saini N, MD, Delgado R, Rondon G, Ciurea SO, MD, Popat UR, MD, Khouri IF, MD, Kebriaei P, MD, Manasanch EE, MD, Hosing C, MD, Patel KK, MD, Lee HC, M, Shpall EJ, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood Journal, 2020. e-Pub 2020.
16. Gaballa MR, MD, Al-Juhaishi T, MD, Bashir Q, MD, Srour SA, MD, MS, Saini N, MD, Ramdial J, MD, Nieto Y, MD, Murphy R, PA-C, Lee HC, MD, Patel KK, MD, Kebriaei P, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood Journal, 2020. e-Pub 2020.
17. Afrough A, MD, Alsfeld LC, MD, Srour SA, MD, MS, Bashir Q, MD, Saini N, MD, Hosing C, MD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Delgado R, Murphy R, PA-C, Manasanch EE, MD, Lee HC, MD, Kaufman GP, MD, Patel KK, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood Journal, 2020. e-Pub 2020.
18. Srour SA, MD, MS, Bashir Q, MD, Milton DR, MS, Nieto Y, MD, Mehta RS, MD, MPH, MS, Saini N, MD, Delgado R, Rondon G, Hosing C, MD, Ciurea SO, MD, Daher M, Popat UR, MD, Khouri IF, MD, Kebriaei P, MD, Manasanch EE, MD, Kaufman GP, MD, Patel KK, MD, Shpall EJ, MD, Lee HC, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood Journal, 2020. e-Pub 2020.
19. Manasanch EE, MD, Han G, Zhang Z, Dang M, Singh M, Khan M, MD, Singh S, Lee HC, MD, Patel KK, MD, Kaufman GP, MD, Amini B, MD, PhD, Bashir Q, MD, Srour SA, MD, MS, Nieto Y, MD, Qazilbash MH, MD, Berkova Z, PhD, Lin P, MD, DM, MDPC, Berry D, MD, PhD, Thomas SK, MD, Weber DM, MD, Futreal P, Wang L, PhD, Orlowski RZ, MD, PhD, Neelapu SS, MD. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood Journal, 2020. e-Pub 2020.
20. Costello CL, MD, Cohen AD, MD, Patel KK, MD, Ali SS, MD, Berdeja JG, MD, Shah N, MD, Ganguly S, MD, Kocoglu MH, MD, Abedi M, MD, Ostertag EM, MD, PhD, Martin CE, PhD, Ghoddussi M, PhD, Shedlock DJ, PhD, McCaigue J, MS, Namini H, PhD, Yalamanchili S, Spear MA, MD, Gregory TK, MD. Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies. Blood Journal, 2020. e-Pub 2020.
21. Becnel MR, Rubin ML, Nair RA, Manasanch EE, Lee HC, KK P, Iyer SP, Thomas SK, Weber DM, Orlowski RZ. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens. Blood Journal 132, 2018. e-Pub 2018.
22. DMCD S, Saliba RM, Patel RO, Bashir QA, Hosing CH, Kebriaei PA, Khouri IF, Nieto YA, Popat UD, Lee HC, Manasanch EE, KK P. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood Journal 132, 2018. e-Pub 2018.
23. Patel RO, Saini NY, Varma AN, Hasan OM, Bashir QA, Delgado R, Popat UD, Hosing CH, Mukherjee AK, Nieto YA, Kebriaei PA, Weber DM, Thomas SK, Lee HC, Manasansh EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. Blood Journal 132, 2018. e-Pub 2018.
24. Thomas SK, Shah JJ, Morphey AN, Lee HC, Manasanch EE, KK P, Miller CP, Phillips SU, Crumpton BN, Johnson RJ, Feng LE, Iyer SW, Amini BE, Weber DM, Orlowski RZ. Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood Journal 132, 2018. e-Pub 2018.
25. Hildebrandt MAT, Callender RA, Belachew AA, Classen C, Lee HC, KK P, Richards TA, Thomas SK, Weber DM, Orlowski RZ, Manasanch EE. Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies. J Clin Oncol 36, 2018. e-Pub 2018.
26. Aboudalle IM, Khan MA, Feng L, Thomas SK, Manasanch EE, KK P, Medeiros LJ, Mehta RO, Bashir Q, Qazilbash MH, Orlowski RZ, Weber DM, Hu SH, Lee HC. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents: Single center experience. J Clin Oncol 36, 2018. e-Pub 2018.
27. Tabchi SA, Nair R, KK P, Lee HC, Thomas SK, Amini BE, Ahmed SA, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian RA, Feng LE, Manasanch EE. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 36, 2018. e-Pub 2018.
28. Chaudhry M, Steiner R, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, Manasanch EE. #1880 Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for multiple Myeloma and WaldenstroM's Macroglobulinemia. Blood ASH 2017 130, 2017. e-Pub 2017.
29. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. #4365 Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood ASH 2017 130, 2017. e-Pub 2017.
30. Thomas SK, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng L, Amini B, Morphey A, Crumpton B, Phillips S, Miller C, Gonzalez M, Orlowski RZ. #840 Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Mutliple Myeloma. Blood ASH 2017 130, 2017. e-Pub 2017.
31. Mathur R, Be B, Hermanson D, He J, Zhang Z, Rengarajan S, Codde R, Wang X, Tan Y, Martin C, Smith J, Lee HC, Manasanch EE, Thomas SK, Patel KK, Weber DM, Davis RE, Orlowski RZ, Ostertag EM, Shedlock D, Yang J, Neelapu SS. #3068 B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood ASH 2017 130, 2017. e-Pub 2017.
32. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, Filipe S, Gariboldi A, Veeramachaneni T, Manasanch EE, Thomas SK, Lee HC, Patel KK, Weber DM, Davis RE, Orlowski RJ, Smith J, Yang J, Neelapu SS. #502 Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple. Blood ASH 2017 130, 2017. e-Pub 2017.
33. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha S, Kim K, Popescu M, Shah N, Bashir Q, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr N, Garfall AL, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW. #3193 Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood ASH 2017 130, 2017. e-Pub 2017.
34. Manasanch EE, Mathur R, Lee HC, Weber DM, Patel KK, Thomas SK, Munoz SC, de Partovi CM, Claussen CM, Lin P, Amini B, Wang L, MA MCJ, Qing Y, Lei F, Baladandayuthapani V, Davis RE, Neelapu SS, Orlowski RZ. #3089 Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma. Blood ASH 2017 130, 2017. e-Pub 2017.
35. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. #399 A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 2017 ASH 130, 2017. e-Pub 2017.
36. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood ASH 2016 128(22):4680, 2016. e-Pub 2016.
37. Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood ASH 2016 128(22):4613, 2016. e-Pub 2016.
38. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood ASH 2016 128(22):4676, 2016. e-Pub 2016.
39. Patel K, Olivares S, Singh H, Hurton LV, Huls MH, Qazilbash MH, Kebriaei P, Champlin RE, Cooper LJN. Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect. Blood ASH 2016 128(22):3366, 2016. e-Pub 2016.
40. Basir Q, El Shazly M, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash M. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood ASH 2016 128(22):3453. e-Pub 2016.
41. Cornelison AM, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood ASH 2016 128(22):5884, 2016. e-Pub 2016.
42. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, Nieto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood ASH 2016 128(22):64, 2016. e-Pub 2016.
43. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood ASH 2016 128(22):5628, 2016. e-Pub 2016.
44. Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel, K, Bock F, Parmar S, Hosing C, Popat UR, Delgado R, Rondon G, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. ASBMT 21(2), 2015. e-Pub 2015.
45. Qazilbash MH, Thall P, Fox PS, Kebriaei P, Bashir Q, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Dinh Y, Hosing C, Popat UR, Lin P, Shah J, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASBMT 21(2), 2015. e-Pub 2015.
46. Badar T, Parmar S, Cornelison AM, Shah N, Bashir Q, Patel K, Hosing C, Popat UR, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. ASBMT 21(2), 2015. e-Pub 2015.
47. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel KK, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH, 2015. e-Pub 2015.
48. Khouri IF, Sui D, Turturro F, Erwin WD, Bassett Jr RL, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Oran B, Olson A, Popat UR, Patel KK, Qazilbash MH, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros LJ, Young A, Jessop KH. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. ASH, 2015. e-Pub 2015.
49. Khouri IF, Saliba RM, Ledesma C, Jabbour EJ, Turturro F, Alatrash G, Ahmed S, Oran B, Patel KK, Olson A, Marin D, Popat UR, Suki TS, Jorgensen JL, Medeiros LJ, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH, 2015. e-Pub 2015.
50. Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. ASH, 2015. e-Pub 2015.
51. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. ASH, 2015. e-Pub 2015.
52. Patel K, Olivares S, Hurton, L, Huls H, Qazilbash M, Champlin R, Cooper LJN. T-Cell Therapy for Multiple Myeloma Using NY-ESO-1+ T-Cell Antigen Presenting Cells (T-APC) Combined with Adoptive Cellular Transfer (ACT) to Augment Immunotherapy. ASH 2014, 2014. e-Pub 2014.
53. Nusrat M, Patel K. Fanconi Anemia Presenting with Symptomatic Pericardial Effusion. ACP Annual Meeting, 2013. e-Pub 2013.
54. Patel K, Orlowski R, Qazilbash M, Shah J. Plasmablastic lymphoma: 28 patient single institution experience. ASH 2013, 2013. e-Pub 2013.
55. Patel K, Qazilbash M. Prognostic role of serum lactate dehydrogenase (LDH) prior to autologous stem cell transplant in Multiple Myeloma. ASH 2012, 2012. e-Pub 2012.
56. Khan D, Patel K, Qazilbash M. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom’s Macroglobulinemia. ASH 2012, 2012. e-Pub 2012.
57. Patel K, Saliba R, Qazilbash M. Autologous stem cell transplantation in Waldenstroms Macroglobulinemia. 2012 International Workshop on Waldenstrom's macroglobulinemia and Multiple Myeloma Symposium, 2012. e-Pub 2012.
58. Patel K, Delasalle K, Orlowski R. Prognositic value of serum lactate dehydrogenase in symptomatic myeloma. ASCO 2012, 2011. e-Pub 2011.
59. Koranne K, Patel K, Escobar M. Escobar M. Acquired Factor VIII inhibitor: a rare complication of Primary Biliary Cirrhosis. ACP Annual Meeting, 2011. e-Pub 2011.
60. Richey S, Culp S, Jonash E, Corn P, Pagliaro L, Tamboli, Patel K, Matin S, Tannir N. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. ASCO 2011, 2011. e-Pub 2011.
61. Cheloni G, Karagkouni D, Nanda S, Torres D, Lina, Bisharat, Saldarriaga I, Ma Y, Wang S, Katopodi X, Pita-Juarez Y, Liegel J, Toros H, Rallis K, Pophali P, Chung DJ, Shah N, Callander NS, Dhakal B, Thinle, Chodon, Munshi NC, Anderson KC, Efebera Y, Hematti P, Lazarus HM, Malek E, McCarthy PL, Ajay K, Nooka, Patel KK, Rapoport AP, Soiffer RJ, Edmund, Waller K, Pasquini MC, Rosenblatt J, Vlachos I, Avigan D. Neoantigen Expression and Expansion of Cytotoxic T Cell Clonotypes in Multiple Myeloma Patients Randomized to Post-Transplant Treatment with a Personalized Cancer Vaccine Under the BM CTN 1401 Multicenter Trial. TANDEM Meetings.
62. Janakiram M, Khouri J, Castaneda O, Shune L, Dima D, Kaur G, De Avila G, Gaballa M, Midha S, Davis J, Wagner C, McGuirk JP, Forsberg P, Reshef R, Lin Y, Afrough A, Anderson Jr LD, Davila ML, Kocoglu MH, Sborov D, Htut M, Hashmi H, Sidana S, Chowdhury A, Patel KK, Hansen DK, Atrash S. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database. American Society for Transplantation and Cellular Therapy Annual Meeting.
63. Galarza Fortuna GM, Sidana S, Hovanky V, Khouri J, Dima D, Kocoglu MH, Forsberg P, Ferreri C, Atrash S, Voorhees PM, Hashmi H, Davis J, Gaballa M, Anto E, De Avila G, Peres L, Patel KK, Hansen DK, Sborov D. Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience. American Society for Transplantation and Cellular Therapy Annual Meeting.
64. Dima D, Afrough A, Anderson L, Anwer F, Atrash S, Banerjee R, Baz R, Castaneda O, Chen A, Cowan A, Davis J, DeJarnette S, Ferreri C, Gaballa M, Garfall A, Goel U, Gonzalez R, Grajales-Cruz A, Hansen D, Herr M, Hosoya H, Julian K, Kaur G, Khouri J, Lee H, Lieberman-Cribbin A, Lin Y, Mikkilineni L, Ouchveridze E, Pasvolsky O, Patel K, Portuguese A, Rana M, Raza S, Razzo B, Richard S, Rossi A, Sannareddy A, Sborov D, Shune L, Sidana S, Susanibar-Adaniya S, Vazquez-Martinez MA, Voorhees P. Teclistamab (Tec) for Patients (pts) with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium.
65. Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Valero YA, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. American Society of Hematology.
66. Ye J, Tang G, Pasvolsky O, Becnel MR, Gaballa MR, Patel KK, Lee HC, Thomas SK, Weber DM, Lin P, Orlowski RZ. Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma. American Society of Hematology.
67. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, Sheeba K. Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis. American Society of Hematology.
68. Dang M, Lee HC, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LY, Berrios D, Pasvolsky O, Gaballa MR, Becnel MR, Ye J, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma. American Society of Hematology.
69. Paul B, Dhodapkar MV, Alsina M, Berdeja JG, Richard S, Vij R, Leleu X, Egan DN, Bergsagel P, Reshef R, Usmani SZ, Truppel-Hartmann A, Basudhar D, Thompson EG, Wu F, Eliason L, Park S, Tran S, Chaudhry M, Siegel DS, Patel KK. Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up.
70. Dillard CM, Gurumurthi A, MBBS, Lee HC, MD, Thomas SK, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Qazilbash MH, MD, Patel KK, MD, MSc, Hildebrandt MA. Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients. American Society of Hematology.
71. Banerjee R, Richards A, Khouri J, Janakiram M, Cicero KI, Dima D, Kocoglu MH, Shune LO, Ouchveridze E, Jain T, Afrough A, Zanwar S, Ferreri C, Pasvolsky O, Mikkilineni L, Purvey S, Peres LC, Freeman CL, Midha S, Beitinjaneh A, Davis JA, Wagner CB, Herr MM, Forsberg PA, Sborov DW, Richard S, Reshef R, Dhakal B, Bachanova V, McGuirk JP, Voorhees PM, Anderson Jr LD, Lin Y, Martin TG, Sidana S, Krina K. Patel, Hansen DK, Cowan AJ, Kaur G. Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium. American Society of Hematology.
72. Lionel A, Seif S, Sun X, Feng L, Gensini L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Patel KP, Weber DM, Orlowski RZ, Thomas SK. Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma. American Society of Hematology.
73. Pasvolsky O, Afrough A, Feng L, Dong W, Richards T, Davis JA, Dima D, Grajales-Cruz A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, PharmD, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Forsberg PA, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Eberwein E, PharmD, Lin C, Blue B, Raza S, Lin Y, Joseph P., Atrash S, Sborov DW, Voorhees PM, Anwer F, Hansen DK, Patel KK, Sidana S, Cowan AJ, Anderson Jr LD, Richard S, Garfall AL, Lee HC, Khouri J. Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. American Society of Hematology.
74. Karagkouni D, Cheloni G, Nanda S, Ma Y, Wang S, Katopodi LX, Saldarriaga I, Pita-Juarez Y, Chung DJ, Shah N, Callander N, Dhakal B, Chodon T, Munshi NC, Anderson KC, Efebera YA, Hematti P, Lazarus HM, Malek E, McCarthy PL, Nooka AK, Patel KK, Rapoport AP, Soiffer RJ, Waller EK, Pasquini MC, Rosenblatt J, Avigan D, Vlachos IS. Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment. American Society of Hematology.
75. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. American Society of Hematology.
76. Elias A, Prakash R, Nair R, Malpica L, Lee HJ, Maples E, Carlson S, Fayad LE, Patel KK, Ahmed S, Iyer SP. Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data. American Society of Hematology.
77. Peres LC, Richards A, Sidana S, Oswald LB, Dima D, Afrough A, Shune LO, Midha S, Castaneda O, Ferreri C, Davis JA, PharmD, Pasvolsky O, Dillard CM, Herr MM, Kocoglu MH, Atrash S, Blue B, Ouchveridze E, McGuirk JP, Wagner CB, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, Avila GD, Purvey S, Hosoya H, Mikkilineni L, Kaur G, Gaballa MR, Forsberg PA, Freeman CL, Janakiram M, Htut M, Asoori S, Kalariya N, Atanackovic D, Dhakal B, Khouri J, Raza S, Reshef R, Alsina M, Locke FL, Nadeem O, Anwer F, Anderson Jr LD, Richard S, Lin Y, Martin T, Voorhees PM, Patel KK, Hansen DK, Sborov DW. Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel. American Society of Hematology.
78. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. American Society of Hematology.
79. Dhakal B, Slade M, Narra R, Mohamed ME, Akhtar OS, Bansal H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye J, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini MC, D'Souza A, Knysh H, Orlowski RZ, Albitar M, Hans C. Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. American Society of Hematology.
80. Dima D, MD, Vazquez-Martinez MA, MD, Davis JA, PharmD, Goel U, MBBS, Afrough A, Sannareddy A, MBBS, Pasvolsky O, MD, Razzo B, MD, Banerjee R, MD, FACP, Khouri J, MD, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, PharmD, DeJarnette S, Portuguese AJ, MD, Gaballa MR, MD, Avila GD, Susanibar-Adaniya S, MD, Raza S, MD, Herr MM, PhD, Ouchveridze E, MD, Richards T, PhD, NP, Hosoya H, MD, PhD, Mikkilineni L, MD, MA, Kaur G, MD, MA, Schrum D, PharmD, Castaneda O, MD, Rossi A, MD, MSc, Lin C, MD, Forsberg PA, MD, Lin Y, MD, PhD, Atrash S, MD, Sborov DW, MD, Shain KH, MD, PhD, Voorhees PM, MD, Richard S, MD, Garfall AL, MD, Hansen DK, MD, Sidana S, MD, Patel KK, MD, MSc, Cowan AJ, MD, Anderson Jr LD, MD, PhD, Lee HC, MD, Anwer F, MD, Ferreri C, MD, Shune LO, MD. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. American Society of Hematology.
81. Patel KK, Manasanch EE, Lee HC, Ye J, Thomas SK, Weber DM, Becnel MR, Gaballa MR, Bansal H, Berkova Z, Neelapu SS, Haymaker CL, Dang M, Wang L, Lizee G, Orlowski RZ. Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM). American Society of Hematology.
82. Rejeski K, MD, Hansen DK, MD, Dos Santos DMC, MD, Silva Corraes ADM, MD, Castaneda O, MD, Dillard CM, MD, Alsdorf W, Frenking JH, MD, Purcarea A, MD, Chhabra S, MBBS, Freeman CL, PhD, MSc, FRCPC, MRCP, Friedrich MJ, MD, PhD, Gaballa MR, MD, Gonzalez R, PharmD, Bin Waqar SH, MD, Hwa YL, APRN, DNP, CNP, Jain MD, MD, PhD, Parrondo RD, MD, Pasvolsky O, MD, Shahbaz W, MD, Shouval R, MD, PhD, Spiess G, PAC, Stephens H, PAC, Theurich S, MD, Bassermann F, MD, Hecker JS, MD, Raab MS, Weisel KC, MD, Locke FL, MD, Subklewe M, MD, Patel KK, MD, MSc, Lin Y, MD, PhD. Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. American Society of Hematology.
83. Dang M, Lee HC, Bansal H, Acevedo-Calado M, Qin L, Tan W, Moreno Rueda LY, Berrios D, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects. American Society of Hematology.
84. Hansen DK, MD, Peres LC, PhD, MPH, Dima D, MD, Richards A, PhD, Shune LO, MD, Afrough A, MD, Midha S, MD, Dhakal B, MBBS, Kocoglu MH, MD, Atrash S, MD, Ferreri C, MD, Castaneda O, MD, Davis JA, PharmD, Ouchveridze E, MD, McGuirk JP, DO, Wagner CB, PharmD, Bansal R, MBBS, Costello P, MS, Smith K, MD, Lieberman-Cribbin A, Avila GD, Purvey S, MD, Hosoya H, MD, PhD, Mikkilineni L, MD, MA, Oswald LB, PhD, Kaur G, MD, MA, Pasvolsky O, MD, Gaballa MR, MD, Herr MM, PhD, Forsberg PA, MD, Janakiram M, MBBS, Htut M, MD, Asoori S, MBBS, MPH, Kalariya N, PhD, RN, Hashmi HS, MD, Reshef R, MD, MSc, Sborov DW, MD, Nadeem O, MD, Anwer F, MD, Khouri J, MD, Raza S, MD, Atanackovic D, MD, Alsina M, MD, Freeman CL, PhD, MSc, FRCPC, MRCP, Locke FL, MD, Voorhees PM, MD, Anderson Jr LD, MD, PhD, Richard S, MD, Martin T, MD, Lin Y, MD, PhD, Patel KK, MD, MSc, Sidana S, MD. Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma. American Society of Hematology.
85. Dhakal B, MBBS, Akhtar OS, MD, Cowan AJ, MD, Richard S, MD, Friend R, Rees MJ, MD, Costello P, MS, Martinez MV, Pasvolsky O, MD, Wagner CB, PharmD, Jensen A, Davis JA, PharmD, Reshef R, MD, MSc, Dima D, Banerjee R, MD, FACP, Bhutani M, MD, Nadeem O, MD, Parrondo RD, MD, Mikkilineni L, MD, MA, Raza S, MD, Kapoor P, MD, Hosoya H, MD, PhD, Chhabra S, MD, Grajales-Cruz A, Gaballa MR, MD, Midha S, MD, Alsina M, MD, Sborov DW, MD, MS, Patel KK, MD, MSc, Lin Y, MD, PhD, Ferreri CJ, MD, Hansen DK, MD, Costa LJ, MD, PhD, Sidana S, MD. Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM). American Society of Hematology.
86. Pasvolsky O, MD, Dima D, MD, Feng L, MS, Dong W, Richards T, PhD, NP, Davis JA, PharmD, Afrough A, Vazquez-Martinez MA, MD, Sannareddy A, MBBS, Goel U, MBBS, Banerjee R, MD, FACP, Khouri J, MD, Cervoni Curet FN, MD, Gaballa MR, MD, Lieberman-Cribbin A, Rana MS, MBBS, Julian K, PharmD, Ferreri CJ, MD, Shune LO, MD, DeJarnette S, Ouchveridze E, MD, Susanibar-Adaniya S, MD, Portuguese AJ, Hosoya H, MD, PhD, Mikkilineni L, MD, MA, Kaur G, MD, MA, Rossi A, MD, MSc, Herr MM, PhD, Schrum D, PharmD, Lin C, MD, Raza S, MD, Lin Y, MD, PhD, Atrash S, MD, McGuirk JP, DO, Sborov DW, MD, Voorhees PM, MD, Anwer F, MD, Alsina M, MD, Freeman CL, PhD, MSc, FRCPC, MRCP, Garfall AL, MD, Sidana S, MD, Cowan AJ, MD, Anderson Jr LD, MD, PhD, Hansen DK, MD, Richard S, MD, Patel KK, MD, MSc, Lee HC, MD, Grajales-Cruz A. Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. American Society of Hematology.
87. Freeman CL, Dhakal B, Kaur G, Maziarz RT, Callander N, Sperling AS, Schinke C, Jakubowiak AJ, Biran N, Sborov DW, Varga C, Deol A, Kanate AS, Koçoğlu MH, Solh MM, Banerjee K, Chan R, Nahas M, Kostic A, Granados E, Jackson C, Heery CR, Welliver T, Patel KK, Frigault M. Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial. American Society of Hematology.
88. Dong S, Anderson L, Bin Waqar SH, Dima D, Kaur G, Khouri J, Patel K, Ravi G. Effect of Obesity on Efficacy and Safety Outcomes of Chimeric Antigen Receptor-T (CAR-T) Therapy in Relapsed Refractory Multiple Myeloma (RRMM). TANDEM Meetings.
89. Banerjee R, Afrough A, Anderson L, Bachanova V, Beitinjaneh A, Bhurtel E, Cicero K, Cowan A, Davis J, Dhakal B, Dima D, Ferreri C, Forsberg P, Freeman C, Hansen D, Herr M, Jain T, Janakiram M, Kaur G, Khouri J, Kocoglu M, Lin Y, Martin T, McGuirk J, Midha S, Mikkilineni L, Pasvolsky O, Patel K, Peres L, Purvey S, Reshef R, Richard S, Richards A, Sborov D, Shune L, Sidana S, Voorhees P, Wagner C, Zanwar S. Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium. TANDEM Meetings.
90. Pasvolsky O, Milton DR, Tanner MR, A Srour QBS, Saini NY, Lin P, Saeed A, Haider AA, Ramdial JL, Nieto Y, Tang G, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Becnel MR, Thomas SK, Robert, Shpall EJ, Champlin RE, H Qazilbash AM. Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. TANDEM Meetings.
91. Afrough A, Anderson L, Anwer F, Atrash S, Banerjee R, Castaneda O, Cowan A, Davis J, Avila GD, DeJarnette S, Dima D, Eberwein E, Ferreri C, Gaballa M, Garfall A, Goel U, Grajales-Cruz A, Hansen D, Herr M, Hosoya H, Julian K, Kaur G, Khouri J, Lee H, Lieberman-Cribbin A, Lin Y, Locke F, McGuirk J, Mikkilineni L, Ouchveridze E, Pasvolsky O, Patel K, Portuguese A, Rana M, Raza S, Razzo B, Richard S, Rossi A, Sannareddy A, Sborov D, Schrum D, Shune L, Sidana S, Susanibar-Adaniya S, Vasquez-Martinez M, Voorhees P. The Impact of Extramedullary Multiple Myeloma on Treatment Outcomes with Teclistamab: U.S. Myeloma Immunotherapy Consortium Real World Experience.
92. Sidana S, Alsina M, Atanackovic D, Atrash S, Bansal R, Chhabra S, Costello P, Avila GD, Dhakal B, Dima D, Ferreri C, Freeman C, Gonzalez R, Hansen D, Herr M, Hosoya H, Hovanky V, Kalariya N, Khouri J, Kocoglu M, Kumar A, Lin Y, Locke F, Mann H, Martin T, McGuirk J, Midha S, Mikkilineni L, Nadeem O, Parrondo R, Patel K, Peres L, Reshef R, Richards A, Sborov D, Shune L, Smith K, Wagner C. Ciltacabtagene Vicluecel (Cilta-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience. TANDEM Meetings.
93. Patel KK. UCART CS1A (SLAMF7 allo CAR). Immune and Cellular Therapies in Multiple Myeloma Workshop.
94. Hansen DK, Sidana S, Peres L, Shune L, Sborov D, Hashmi H, Kocoglu M, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Alsina M, McGuirk J, Locke F, Patel K. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience. American Society of Clinical Oncology Annual Meeting.
95. Hashmi H, Hansen DK, Peres L, Castaneda Puglianini O, Freeman C, De Avila G, Sidana S, Shune L, Sborov D, Davis J, Wagner C, Kocoglu H, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Sannareddy A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel K, Alsina M. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience. American Society of Hematology Annual Meeting.
96. Khouri J, Li H, Hansen DK, Sidana S, Shune L, DeJarnette S, Anwer F, Sborov D, Wagner C, Kocoglu H, Atrash S, Voorhees P, Valent J, Peres L, Hovanky V, Simmons G, Dima D, Kalariya N, Afrough A, Kaur G, Sannareddy A, Ferreri C, Davis J, McGuirk J, Locke F, Baz R, Hamilton B, Alsina M, Sauter C, Hashmi H, Patel K. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience. American Society of Hematology Annual Meeting.
97. Ferreri C, Hildebrandt M, Hashmi H, Shune L, McGuirk J, Sborov D, Wagner C, Kocoglu M, Atrash S, Voorhees P, Khouri J, Dima D, Afrough A, Sannareddy A, Simmons G, Davis J, Kalariya N, Peres L, Alsina M, Locke F, Sidana S, Hansen DK, Patel K, Castaneda Puglianini O. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience. American Society of Hematology Annual Meeting.
98. Sidana S, Peres L, Hashmi H, Hosoya H, Ferreri C, Atrash S, Khouri J, Voorhees P, Dima D, Simmons G, Kalariya N, Hovanky V, Bharadwaj S, Arai S, Miklos D, Wagner C, Davis J, Sborov D, Nishihori T, Alsina M, Locke F, Gonzalez R, Kocoglu M, Sannareddy A, Afrough A, McGuirk J, Shune L, Patel K, Hansen DK. Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience. American Society of Hematology Annual Meeting.
99. Peres L, Oswald L, Dillard C, De Avila G, Nishihori T, Blue B, Freeman C, Locke F, Alsina M, Castaneda Puglianini O, Shune L, Sborov D, Wagner C, Dima D, Hashmi H, Davis J, Kocoglu H, Atrash S, Simmons G, Kalariya N, Ferreri C, Sannareddy A, Afrough A, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy. American Society of Hematology Annual Meeting.
100. Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Dima D, Freeman CL, Castaneda Puglianini OA, Kocoglu MH, Atrash S, Voorhees PM, Shune L, Simmons G, Sborov DW, Ferreri CJ, Burton Wagner C, Patel KK, Khouri J, Anderson LD, Lin Y. . Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium. American Society of Clinical Oncology Annual Meeting.
101. Hansen DK, Patel K, Peres L, Kocoglu M, Shune L, Simmons G, Ferreri C, Atrash S, Parrondo R, Chabra S, Costello P, Midha S, Alsina M, Voorhees P, Htut M, Sborov D, Khouri J, Janakiram M, Lin Y, Sidana S. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. International Myeloma Society Annual Meeting.
102. Wagner CB, Sweiss K, Anto E, Gonzalez R, Castaneda Puglianini OA, Freeman CL, Ionescu F, Patel KK, Ferreri C, Gaballa M, Shune L, McGuirk JP, Sidana S, Hovanky V, Khouri J, Dima D, Hashmi H, Davis JA, Afrough A, Kaur G, Anderson Jr LD, Forsberg PA, Herr M, Hansen DK, Sborov D, Kocoglu MH. Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium. Annual Meeting of the American Society of Hematology.
103. Midha S, Gurumurthi A, Costello P, Redd RA, Freeman CL, Castaneda O, Gonzalez R, Ionescu F, Gaballa M, Kalariya N, Khouri J, Dima D, Kocoglu MH, Sborov D, Wagner CB, Atrash S, Voorhees PM, Hashmi H, Davis JA, Forsberg PA, McGuirk JP, Shune L, Herr M, Reshef R, Lin Y, Htut M, Martin T, Sidana S, Hansen DK, Nadeem O, Patel KK. Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Annual Meeting of the American Society of Hematology.

Book Chapters

1. Ferreri, C, Afrough, A, Dillard, C, Patel, K. Chimeric Antigen Receptor Therapy in Multiple Myeloma, 309-329, 2023.
2. Becnel M, Kaufman GP, Manasanch EE, Patel K, Lee HC, Orlowski RZ, Thomas S. Chapter 15: Waldenström Macroglobulinemia. In: The MD Anderson Manual of Medical Oncology. 4, 2022.
3. Kaufman GP, Qazilbash MH, Patel K, Thomas S, Orlowski RZ, Lee HC. Chapter 14: Systemic Immunoglobulin Light Chain Amyloidosis. In: The MD Anderson Manual for Medical Oncology. 4, 2022.
4. Lin P, Kaufman GP, Lee HC, Manasanch EE, Becnel M, Thomas S, Weber D, Orlowski RZ, Patel K. Chapter 16: Multiple Myeloma. In: The MD Anderson Manual of Medical Oncology. 4, 2022.
5. Amini B, Patel K, Westmark RM, Westmark KD, Gonzalez AA. Approach to the Solitary Vertebral Lesion on Magnetic Resonance Imaging. In: Incidental Findings in Neuroimaging and Their Management, 2020.
6. Nair, R, Patel, K. What the intensivists need to know about critically ill myeloma patients, 1513-1530, 2019.
7. Nair, R, Patel, K. What the intensivists need to know about critically ill Lymphoma patients, 1499-1512, 2019.
8. Patel K, Moyes J, Cooper LJN. Cell-based Cancer Immunotherapy, 2017.
9. Lee HC, Patel K, Kongtim P, Parmar S, Lin P, Qazilbash MH, Thomas S, Manasanch EE. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MD Anderson Manual for Medical Oncology, 2016.

Letters to the Editor

1. Banerjee, R, Kaur, G, Razzo, BM, Portuguese, AJ, Sidana, S, Richards, TA, Grajales-Cruz, A, Richard, S, Shune, L, Khouri, J, Dima, D, Lee, HC, Patel, K, Pasvolsky, O, Vazquez-Martinez, M, Hansen, DK, Afrough, A, Davis, JA, Hashmi, H, Atrash, S, Ferreri, C, Julian, K, Herr, M, Midha, S, Costello, P, Forsberg, P, de Menezes Silva Corraes, A, Lin, Y, Cowan, AJ, Anderson, L, Garfall, A. Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response. American journal of hematology 101: 169-173, 2026.
2. Rees, MJ, Khouri, J, Grajales-Cruz, A, Zanwar, S, Goel, U, Midha, S, Kelley, J, Castaneda Puglianini, OA, Corraes, AS, Raza, S, Davis, JA, Green, K, Hansen, DK, Banerjee, R, Sidana, S, Patel, K, Bianchi, G, Sborov, D, Lee, S, Kumar, SK, Baz, R, Anwer, F, Mikkilineni, L, Nadeem, O, Lin, Y, Anderson, L. The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis. American journal of hematology 101: 187-192, 2026.
3. Chohan, KL, Gensini, L, Seif, S, Sun, X, Feng, L, Becnel, M, Gaballa, MM, Lee, HC, Pasvolsky, O, Patel, K, Ye, JC, Weber, DM, Orlowski, R, Thomas, SK. Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood cancer journal 15, 2025.
4. Banerjee, R, Richards, A, Midha, S, Afrough, A, Anwer, F, Atanackovic, D, Atrash, S, Bachanova, V, Beitinjaneh, AM, Bhurtel, E, Castaneda Puglianini, OA, Chhabra, S, Cicero, KI, Davis, JA, Dhakal, B, Dima, D, Ferreri, C, Forsberg, P, Freeman, C, Herr, M, Jain, T, Janakiram, M, Khouri, J, Kocoglu, MH, Kumar, A, Liu, Y, Locke, FL, McGuirk, J, Mikkilineni, L, Nadeem, O, Parrondo, RD, Pasvolsky, O, Peres, LC, Purvey, S, Raza, S, Reshef, R, Richard, S, Rossi, A, Sborov, D, Shune, L, Wagner, C, Zanwar, S, Sidana, S, Patel, K, Hansen, DK, Kumar, SK, Lin, Y, Martin, T, Voorhees, PM, Anderson, L, Cowan, AJ, Kaur, G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Advances 9: 2336-2340, 2025.
5. Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
6. Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J 14: 63, 2024.
7. Hansen, DK, Sidana, S, Peres, LC, Patel, K. Reply to R. Chakraborty et al. Journal of Clinical Oncology 41: 3658-3659, 2023.
8. Pasvolsky, O, Saliba, RM, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. British Journal of Haematology 201: e37-e41, 2023.
9. Chiu, CY, Patel, K, Thomas, SK, Khawaja, F, Dailey Garnes, NM, Lee, HC, Ohanian, M, Jiang, Y, Wang, LS, Hwang, JP, Torres, HA. Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatology International 17: 509-511, 2023.
10. Mohan, M, Becnel, M, Shah, UA, Dong, H, Gundarlapalli, S, Peterson, T, Orozco, JS, Horowitz, S, Chhabra, S, Dhakal, B, Thanendrarajan, S, Radhakrishnan, SV, Al-Hadidi, SA, Tan, CR, Mailankody, S, Hultcrantz, M, Korde, N, Hassoun, H, Lesokhin, AM, Thomas, SK, Patel, K, Manasanch, EE, Weber, DM, Szabo, A, Kaufman, GP, Lee, HC, Zangari, M, Van Rhee, F, Usmani, S, D'Souza, A, Orlowski, R, Schinke, C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma. American journal of hematology 97: E276-E280, 2022.
11. Patel, R, Ma, J, Bashir, Q, Delgado, R, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Daher, M, Mehta, RS, Srour, S, Weber, DM, Thomas, SK, Lee, HC, Patel, K, Orlowski, R, Shpall, E, Champlin, RE, Saini, N, Qazilbash, MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites. American journal of hematology 96: E455-E457, 2021.
12. Srour, S, Milton, D, Bashir, Q, Nieto, Y, Saini, N, Daher, M, Ramdial, JL, Im, JS, Hosing, C, Delgado, R, Manasanch, EE, Lee, HC, Thomas, SK, Kaufman, GP, Patel, K, Popat, UR, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106: 3211-3214, 2021.
13. Kunacheewa, C, Feng, L, Manasanch, EE, Bashir, Q, Patel, K, Mehta, RS, Kaufman, GP, Srour, S, Saini, N, Iyer, SP, Thomas, SK, Weber, DM, Orlowski, R, Qazilbash, MH, Lee, HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. British Journal of Haematology 193: e23-e26, 2021.
14. Manasanch, EE, Berrios, D, Fountain, E, Claussen, C, Chuang, T, Kaufman, GP, Amini, B, Bashir, Q, Nieto, Y, Qazilbash, MH, Patel, K, Thomas, SK, Weber, DM, Berkova, Z, Toruner, GA, Lin, P, Feng, L, Lee, HC, Orlowski, R, Kunacheewa, C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. British Journal of Haematology 192: e115-e120, 2021.
15. Manasanch, EE, Mulanovich, VE, Manzano, JM, Gaeta, MS, Becnel, M, Kaufman, GP, Lee, HC, Amini, B, Thomas, SK, Iyer, SP, Weber, DM, Berkova, Z, Flowers, CR, Orlowski, R, Patel, K. SARS-CoV-2 in multiple myeloma. Leukemia and Lymphoma 61: 2763-2766, 2020.
16. Lee, HC, Shah, JJ, Feng, L, Manasanch, EE, Lu, R, Morphey, A, Crumpton, B, Patel, K, Wang, L, Alexanian, R, Thomas, SK, Weber, DM, Orlowski, R. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood cancer journal 9, 2019.
17. Saini, N, Patel, R, Varma, A, Bashir, Q, Delgado, R, Rondon, G, Mukherjee, A, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Orlowski, R, Champlin, RE, Qazilbash, MH, Patel, K. Outcomes of autologous stem cell transplantation in Waldenström’s macroglobulinemia. Annals of Hematology 98: 2233-2235, 2019.
18. Saini, N, Patel, R, Varma, A, Bashir, Q, Delgado, R, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Orlowski, R, Champlin, RE, Qazilbash, MH, Patel, K. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. American journal of hematology 94: E72-E74, 2019.
19. Saini, N, Patel, R, Varma, A, Bashir, Q, Delgado, R, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. American journal of hematology 94: E2-E5, 2019.
20. Mohyuddin, GR, Faisal, MS, Badar, T, Shah, ND, Bashir, Q, Patel, K, Hosing, C, Popat, UR, Rondon, G, Delgado, R, Shah, JJ, Weber, DM, Thomas, SK, Manasanch, EE, Orlowski, R, Champlin, RE, Qazilbash, MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma. Leukemia and Lymphoma 59: 515-518, 2018.
21. Patel, K, Nusrat, M, Shah, ND, Bashir, Q, Parmar, S, Shah, J, Thomas, SK, Weber, DM, Orlowski, R, Champlin, RE, Qazilbash, MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone marrow transplantation 49: 465-466, 2014.